

## Contents

---

<b>Εισαγωγικό σημείωμα Διευθυντή Σύνταξης</b> Δ.Θ. ΚΑΡΑΜΗΤΣΟΣ	189
--	-----

---

<b>Χαιρετισμός Προέδρου Συνεδρίου</b> Δ.Μ. ΓΡΕΚΑΣ	190
--	-----

---

### NEW TRENDS IN DIABETIC NEPHROPATHY

---

#### LECTURE

---

<b>Adamantios Korais and Greek education</b> N.P. TERZIS	193
---	-----

---

<b>Genetics of diabetes and its complications. Where do we go next?</b> C. POLYCHRONAKOS	194
---	-----

---

#### ROUND TABLE

---

<b>Hyperglycemia and TGF-VEGF growth factors</b> F. ILIADIS	195
--	-----

---

<b>Diabetic nephropathy: the role of endothelial dysfunction</b> K. PALETAS	197
--	-----

---

<b>TRPC6 channel signaling in response to angiotensin II type 1 receptors is essential for the preservation of the podocyte cytoskeleton</b> A. GREKA	198
--	-----

---

#### LECTURE

---

<b>Mechanisms of progression and management</b> G. REMUZZI	199
---	-----

---

#### ROUND TABLE

---

<b>Histopathologic renal damage in early and late diabetic nephropathy</b> G. KARAYANNOPOULOU	200
--	-----

---

<b>Early and late renal changes in diabetic nephropathy</b> A. RAPTIS	202
--	-----

---

#### LECTURE

---

<b>Diabetic renal disease: Changing paradigms</b> E. MOGENSEN	204
--	-----

---

<b>The role of the podocytes in the pathogenesis and treatment of proteinuria</b> P. MUNDEL	206
--	-----

---

#### **SATELLITE SYMPOSIUM**

---

<b>The role of renin inhibitors in the lowering of proteinuria for renal and cardiovascular protection of patients with diabetic nephropathy</b> G. BAKRIS, G. REMUZZI	207
---	-----

---

#### **LECTURE**

---

<b>Pathogenetic role of autonomic neuropathy in the development of diabetic nephropathy</b> T. DIDANGELOS	209
--	-----

---

#### **ROUND TABLE**

---

<b>Glycemic control at early diabetic nephropathy</b> S. BAKATSELOS	211
--	-----

---

<b>Inhibition of production of advanced glycation and products and protein kinase C</b> A. ZANTIDIS	213
--	-----

---

<b>Endothelin inhibition in patients with diabetic nephropathy</b> S. DOUMA	215
--	-----

---

#### **LECTURE**

---

<b>Obesity and glomerular disease</b> D.S. GOUMENOS	216
--	-----

---

#### **ROUND TABLE**

---

<b>Arterial hypertension in diabetes mellitus and diabetic nephropathy</b> C. SAVOPOULOS, G. NTAIOS, A. HATZITOLIOS	218
--	-----

---

<b>Dyslipidemia and atherosclerosis in diabetes mellitus and diabetic nephropathy</b> V.G. ATHYROS	220
---	-----

---

<b>Insulin resistance and diabetic nephropathy</b> P.A. SARAFIDIS	222
--	-----

---

<b>Cardiovascular risks in diabetic nephropathy</b> S. LIAKOS	225
--	-----

---

#### **LECTURE**

---

<b>Renal, pancreas and islet transplantation for the diabetic patient with end-stage renal disease</b> C. FOURTOUNAS	228
---	-----

---

## **ROUND TABLE**

---

**Secondary hyperparathyroidism in diabetic nephropathy**  
M. NIKODIMOPOULOU 230

---

**Pathogenesis of anemia in diabetic nephropathy**  
M. PAPAIOANNOU 232

---

## **LECTURE**

---

**End stage of diabetic nephropathy: therapeutical management with chronic maintenance hemodialysis**  
A. SIOULIS 234

---

**End-stage diabetic nephropathy: Treatment management with peritoneal dialysis**  
E. BALASKAS 236

---

**TRPC6 channel signaling in response to angiotensin II type 1 receptors is essential for the preservation of the podocyte cytoskeleton**  
A. GREKA 241

---

## **SATELLITE SYMPOSIUM**

---

**Cardio-renal syndrome in type 2 diabetes and diabetic nephropathy: The role of vitamin D receptors**  
G.L. BAKRIS 242

---